Compare SMTI & ACIU Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | SMTI | ACIU |
|---|---|---|
| Founded | 1982 | 2003 |
| Country | United States | Switzerland |
| Employees | N/A | N/A |
| Industry | Medical/Dental Instruments | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 208.2M | 244.3M |
| IPO Year | 2008 | 2015 |
| Metric | SMTI | ACIU |
|---|---|---|
| Price | $23.97 | $2.59 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 2 | 2 |
| Target Price | ★ $34.00 | $10.00 |
| AVG Volume (30 Days) | 59.5K | ★ 283.6K |
| Earning Date | 05-12-2026 | 05-12-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 0.05 | N/A |
| Revenue | ★ $15,586,976.00 | N/A |
| Revenue This Year | $17.31 | $706.75 |
| Revenue Next Year | $12.48 | $321.13 |
| P/E Ratio | $484.60 | ★ N/A |
| Revenue Growth | ★ 32.47 | N/A |
| 52 Week Low | $16.05 | $2.00 |
| 52 Week High | $35.70 | $4.00 |
| Indicator | SMTI | ACIU |
|---|---|---|
| Relative Strength Index (RSI) | 56.82 | 53.77 |
| Support Level | $20.47 | $2.58 |
| Resistance Level | $26.48 | $2.66 |
| Average True Range (ATR) | 1.44 | 0.15 |
| MACD | 0.08 | 0.03 |
| Stochastic Oscillator | 67.05 | 85.42 |
Sanara MedTech Inc is a medical technology company focused on developing and commercializing technologies to improve clinical outcomes and reduce healthcare expenditures in the surgical market. It markets and sells soft tissue repair and bone fusion products for use in operating rooms and sterile environments. Its soft tissue repair products include CellerateRX Surgical Powder, a hydrolyzed collagen used in management of surgical wounds, and BIASURGE Surgical Solution, a sterile no-rinse solution for wound irrigation, while its bone fusion products include BiFORM Bioactive Moldable Matrix, an osteoconductive implant that supports bone growth, and ALLOCYTE Plus Viable Bone Matrix, a human allograft cellular bone matrix containing bone-derived progenitor cells and conformable bone fibers.
AC Immune SA is a clinical stage biopharmaceutical company advancing a portfolio of programs strategically focused on pioneering Precision Medicine for neurodegenerative diseases. The company uses its proprietary technology platforms to discover, design, and develop novel proprietary small molecules, antibodies, and vaccines for the prevention, diagnosis, and treatment of neurodegenerative diseases associated with protein misfolding. The company has one segment. The company currently focuses mostly of its resources on discovering and developing therapeutic and diagnostic products targeting misfolded proteins. The company's pipeline consists of ACI-24.060, Crenezumab, ACI-35.030, Semorinemab, ACI-7104.056, and others.